Analysts expect Heat Biologics Inc (NASDAQ:HTBX) to report earnings of ($0.06) per share for the current quarter, according to Zacks. Three analysts have issued estimates for Heat Biologics’ earnings, with estimates ranging from ($0.16) to $0.09. Heat Biologics posted earnings per share of ($0.60) in the same quarter last year, which suggests a positive year over year growth rate of 90%. The business is scheduled to issue its next earnings results on Monday, November 12th.

According to Zacks, analysts expect that Heat Biologics will report full year earnings of ($0.69) per share for the current year, with EPS estimates ranging from ($0.81) to ($0.62). For the next year, analysts expect that the business will post earnings of ($0.72) per share, with EPS estimates ranging from ($0.75) to ($0.70). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Heat Biologics.

Heat Biologics (NASDAQ:HTBX) last posted its quarterly earnings data on Tuesday, August 14th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.09). The business had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.11 million. Heat Biologics had a negative return on equity of 116.28% and a negative net margin of 437.62%.

A number of research firms have recently weighed in on HTBX. Brookline Cap M restated a “buy” rating on shares of Heat Biologics in a research report on Wednesday, August 1st. HC Wainwright began coverage on Heat Biologics in a research report on Tuesday, June 26th. They set a “buy” rating and a $6.00 target price for the company. Finally, Eurobank EFG began coverage on Heat Biologics in a research report on Monday, July 9th. They set a “buy” rating and a $11.00 target price for the company.

HTBX stock opened at $1.82 on Monday. Heat Biologics has a twelve month low of $1.09 and a twelve month high of $7.21.

An institutional investor recently bought a new position in Heat Biologics stock. Northern Trust Corp bought a new position in shares of Heat Biologics Inc (NASDAQ:HTBX) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 51,512 shares of the biopharmaceutical company’s stock, valued at approximately $111,000. Northern Trust Corp owned about 0.22% of Heat Biologics as of its most recent SEC filing. Institutional investors own 4.41% of the company’s stock.

Heat Biologics Company Profile

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Featured Story: What are trading strategies for the 52-week high/low?

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with's FREE daily email newsletter.